Table 2.

Factors associated with the number of NMS in patients with PD.

	Unadjusted model			Adjusted model
	B	95%CI	P-value	B	95%CI	P-value
Female sex	0.153	0.037–0.628	0.009*	0.416	0.110–1.571	0.196
Age	1.145	1.074–1.221	<0.001*	1.112	1.044–1.184	0.001*
Disease duration	1.573	1.007–2.458	0.047*	1.078	0.684–1.698	0.746
Education	0.971	0.818–1.154	0.741	1.045	0.891–1.225	0.588
LEDD	1.005	1.002–1.008	0.001*	1.002	0.998–1.006	0.360
Use of levodopa	10.912	1.768–67.357	0.010*	2.024	0.213–19.242	0.539
Use of dopamine receptor	1.636	0.275–9.755	0.589	0.421	0.066–2.676	0.359
Use of antidepressant	3.087	0.214–44.556	0.408	2.682	0.235–30.662	0.427
UPDRS III	1.172	1.097–1.251	<0.001*	1.124	1.053–1.201	<0.001*

*Significant difference.

NMS non-motor symptoms, PD parkinson’s disease, LEDD levodopa equivalent daily dose, UPDRS unified parkinson’s disease rating scale.